Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

Hagop Kantarjian, Neil P. Shah, Andreas Hochhaus, Jorge Cortes, Sandip Shah, Manuel Ayala, Beatriz Moiraghi, Zhixiang Shen, Jiri Mayer, Ricardo Pasquini, Hirohisa Nakamae, Françoise Huguet, Concepción Boqué, Charles Chuah, Eric Bleickardt, M. Brigid Bradley-Garelik, Chao Zhu, Ted Szatrowski, David Shapiro, Michele Baccarani

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Treatment with dasatinib, a highly potent BCR-ABL kinase inhibitor, has resulted in high rates of complete cytogenetic response and progression-free survival among patients with chronic myeloid leukemia (CML) in the chronic phase, after failure of imatinib treatment. We assessed the efficacy and safety of dasatinib, as compared with imatinib, for the first-line treatment of chronic-phase CML. METHODS: In a multinational study, 519 patients with newly diagnosed chronic-phase CML were randomly assigned to receive dasatinib at a dose of 100 mg once daily (259 patients) or imatinib at a dose of 400 mg once daily (260 patients). The primary end point was complete cytogenetic response by 12 months, confirmed on two consecutive assessments at least 28 days apart. Secondary end points, including major molecular response, were tested at a significance level of 0.0001 to adjust for multiple comparisons. RESULTS: After a minimum follow-up of 12 months, the rate of confirmed complete cytogenetic response was higher with dasatinib than with imatinib (77% vs. 66%, P=0.007), as was the rate of complete cytogenetic response observed on at least one assessment (83% vs. 72%, P=0.001). The rate of major molecular response was higher with dasatinib than with imatinib (46% vs. 28%, P<0.0001), and responses were achieved in a shorter time with dasatinib (P<0.0001). Progression to the accelerated or blastic phase of CML occurred in 5 patients who were receiving dasatinib (1.9%) and in 9 patients who were receiving imatinib (3.5%). The safety profiles of the two treatments were similar. CONCLUSIONS: Dasatinib, administered once daily, as compared with imatinib, administered once daily, induced significantly higher and faster rates of complete cytogenetic response and major molecular response. Since achieving complete cytogenetic response within 12 months has been associated with better long-term, progression-free survival, dasatinib may improve the long-term outcomes among patients with newly diagnosed chronic-phase CML. (ClinicalTrials.gov number, NCT00481247.)

Original languageEnglish (US)
Pages (from-to)2260-2270
Number of pages11
JournalNew England Journal of Medicine
Volume362
Issue number24
DOIs
StatePublished - Jun 17 2010
Externally publishedYes

Fingerprint

Leukemia, Myeloid, Chronic Phase
Cytogenetics
Disease-Free Survival
Safety
Imatinib Mesylate
Dasatinib
Treatment Failure
Phosphotransferases
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kantarjian, H., Shah, N. P., Hochhaus, A., Cortes, J., Shah, S., Ayala, M., ... Baccarani, M. (2010). Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. New England Journal of Medicine, 362(24), 2260-2270. https://doi.org/10.1056/NEJMoa1002315

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. / Kantarjian, Hagop; Shah, Neil P.; Hochhaus, Andreas; Cortes, Jorge; Shah, Sandip; Ayala, Manuel; Moiraghi, Beatriz; Shen, Zhixiang; Mayer, Jiri; Pasquini, Ricardo; Nakamae, Hirohisa; Huguet, Françoise; Boqué, Concepción; Chuah, Charles; Bleickardt, Eric; Bradley-Garelik, M. Brigid; Zhu, Chao; Szatrowski, Ted; Shapiro, David; Baccarani, Michele.

In: New England Journal of Medicine, Vol. 362, No. 24, 17.06.2010, p. 2260-2270.

Research output: Contribution to journalArticle

Kantarjian, H, Shah, NP, Hochhaus, A, Cortes, J, Shah, S, Ayala, M, Moiraghi, B, Shen, Z, Mayer, J, Pasquini, R, Nakamae, H, Huguet, F, Boqué, C, Chuah, C, Bleickardt, E, Bradley-Garelik, MB, Zhu, C, Szatrowski, T, Shapiro, D & Baccarani, M 2010, 'Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia', New England Journal of Medicine, vol. 362, no. 24, pp. 2260-2270. https://doi.org/10.1056/NEJMoa1002315
Kantarjian, Hagop ; Shah, Neil P. ; Hochhaus, Andreas ; Cortes, Jorge ; Shah, Sandip ; Ayala, Manuel ; Moiraghi, Beatriz ; Shen, Zhixiang ; Mayer, Jiri ; Pasquini, Ricardo ; Nakamae, Hirohisa ; Huguet, Françoise ; Boqué, Concepción ; Chuah, Charles ; Bleickardt, Eric ; Bradley-Garelik, M. Brigid ; Zhu, Chao ; Szatrowski, Ted ; Shapiro, David ; Baccarani, Michele. / Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. In: New England Journal of Medicine. 2010 ; Vol. 362, No. 24. pp. 2260-2270.
@article{a88d9409b2ab4dd491db79c5c5d0a776,
title = "Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia",
abstract = "BACKGROUND: Treatment with dasatinib, a highly potent BCR-ABL kinase inhibitor, has resulted in high rates of complete cytogenetic response and progression-free survival among patients with chronic myeloid leukemia (CML) in the chronic phase, after failure of imatinib treatment. We assessed the efficacy and safety of dasatinib, as compared with imatinib, for the first-line treatment of chronic-phase CML. METHODS: In a multinational study, 519 patients with newly diagnosed chronic-phase CML were randomly assigned to receive dasatinib at a dose of 100 mg once daily (259 patients) or imatinib at a dose of 400 mg once daily (260 patients). The primary end point was complete cytogenetic response by 12 months, confirmed on two consecutive assessments at least 28 days apart. Secondary end points, including major molecular response, were tested at a significance level of 0.0001 to adjust for multiple comparisons. RESULTS: After a minimum follow-up of 12 months, the rate of confirmed complete cytogenetic response was higher with dasatinib than with imatinib (77{\%} vs. 66{\%}, P=0.007), as was the rate of complete cytogenetic response observed on at least one assessment (83{\%} vs. 72{\%}, P=0.001). The rate of major molecular response was higher with dasatinib than with imatinib (46{\%} vs. 28{\%}, P<0.0001), and responses were achieved in a shorter time with dasatinib (P<0.0001). Progression to the accelerated or blastic phase of CML occurred in 5 patients who were receiving dasatinib (1.9{\%}) and in 9 patients who were receiving imatinib (3.5{\%}). The safety profiles of the two treatments were similar. CONCLUSIONS: Dasatinib, administered once daily, as compared with imatinib, administered once daily, induced significantly higher and faster rates of complete cytogenetic response and major molecular response. Since achieving complete cytogenetic response within 12 months has been associated with better long-term, progression-free survival, dasatinib may improve the long-term outcomes among patients with newly diagnosed chronic-phase CML. (ClinicalTrials.gov number, NCT00481247.)",
author = "Hagop Kantarjian and Shah, {Neil P.} and Andreas Hochhaus and Jorge Cortes and Sandip Shah and Manuel Ayala and Beatriz Moiraghi and Zhixiang Shen and Jiri Mayer and Ricardo Pasquini and Hirohisa Nakamae and Fran{\cc}oise Huguet and Concepci{\'o}n Boqu{\'e} and Charles Chuah and Eric Bleickardt and Bradley-Garelik, {M. Brigid} and Chao Zhu and Ted Szatrowski and David Shapiro and Michele Baccarani",
year = "2010",
month = "6",
day = "17",
doi = "10.1056/NEJMoa1002315",
language = "English (US)",
volume = "362",
pages = "2260--2270",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "24",

}

TY - JOUR

T1 - Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

AU - Kantarjian, Hagop

AU - Shah, Neil P.

AU - Hochhaus, Andreas

AU - Cortes, Jorge

AU - Shah, Sandip

AU - Ayala, Manuel

AU - Moiraghi, Beatriz

AU - Shen, Zhixiang

AU - Mayer, Jiri

AU - Pasquini, Ricardo

AU - Nakamae, Hirohisa

AU - Huguet, Françoise

AU - Boqué, Concepción

AU - Chuah, Charles

AU - Bleickardt, Eric

AU - Bradley-Garelik, M. Brigid

AU - Zhu, Chao

AU - Szatrowski, Ted

AU - Shapiro, David

AU - Baccarani, Michele

PY - 2010/6/17

Y1 - 2010/6/17

N2 - BACKGROUND: Treatment with dasatinib, a highly potent BCR-ABL kinase inhibitor, has resulted in high rates of complete cytogenetic response and progression-free survival among patients with chronic myeloid leukemia (CML) in the chronic phase, after failure of imatinib treatment. We assessed the efficacy and safety of dasatinib, as compared with imatinib, for the first-line treatment of chronic-phase CML. METHODS: In a multinational study, 519 patients with newly diagnosed chronic-phase CML were randomly assigned to receive dasatinib at a dose of 100 mg once daily (259 patients) or imatinib at a dose of 400 mg once daily (260 patients). The primary end point was complete cytogenetic response by 12 months, confirmed on two consecutive assessments at least 28 days apart. Secondary end points, including major molecular response, were tested at a significance level of 0.0001 to adjust for multiple comparisons. RESULTS: After a minimum follow-up of 12 months, the rate of confirmed complete cytogenetic response was higher with dasatinib than with imatinib (77% vs. 66%, P=0.007), as was the rate of complete cytogenetic response observed on at least one assessment (83% vs. 72%, P=0.001). The rate of major molecular response was higher with dasatinib than with imatinib (46% vs. 28%, P<0.0001), and responses were achieved in a shorter time with dasatinib (P<0.0001). Progression to the accelerated or blastic phase of CML occurred in 5 patients who were receiving dasatinib (1.9%) and in 9 patients who were receiving imatinib (3.5%). The safety profiles of the two treatments were similar. CONCLUSIONS: Dasatinib, administered once daily, as compared with imatinib, administered once daily, induced significantly higher and faster rates of complete cytogenetic response and major molecular response. Since achieving complete cytogenetic response within 12 months has been associated with better long-term, progression-free survival, dasatinib may improve the long-term outcomes among patients with newly diagnosed chronic-phase CML. (ClinicalTrials.gov number, NCT00481247.)

AB - BACKGROUND: Treatment with dasatinib, a highly potent BCR-ABL kinase inhibitor, has resulted in high rates of complete cytogenetic response and progression-free survival among patients with chronic myeloid leukemia (CML) in the chronic phase, after failure of imatinib treatment. We assessed the efficacy and safety of dasatinib, as compared with imatinib, for the first-line treatment of chronic-phase CML. METHODS: In a multinational study, 519 patients with newly diagnosed chronic-phase CML were randomly assigned to receive dasatinib at a dose of 100 mg once daily (259 patients) or imatinib at a dose of 400 mg once daily (260 patients). The primary end point was complete cytogenetic response by 12 months, confirmed on two consecutive assessments at least 28 days apart. Secondary end points, including major molecular response, were tested at a significance level of 0.0001 to adjust for multiple comparisons. RESULTS: After a minimum follow-up of 12 months, the rate of confirmed complete cytogenetic response was higher with dasatinib than with imatinib (77% vs. 66%, P=0.007), as was the rate of complete cytogenetic response observed on at least one assessment (83% vs. 72%, P=0.001). The rate of major molecular response was higher with dasatinib than with imatinib (46% vs. 28%, P<0.0001), and responses were achieved in a shorter time with dasatinib (P<0.0001). Progression to the accelerated or blastic phase of CML occurred in 5 patients who were receiving dasatinib (1.9%) and in 9 patients who were receiving imatinib (3.5%). The safety profiles of the two treatments were similar. CONCLUSIONS: Dasatinib, administered once daily, as compared with imatinib, administered once daily, induced significantly higher and faster rates of complete cytogenetic response and major molecular response. Since achieving complete cytogenetic response within 12 months has been associated with better long-term, progression-free survival, dasatinib may improve the long-term outcomes among patients with newly diagnosed chronic-phase CML. (ClinicalTrials.gov number, NCT00481247.)

UR - http://www.scopus.com/inward/record.url?scp=77953725855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953725855&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa1002315

DO - 10.1056/NEJMoa1002315

M3 - Article

C2 - 20525995

AN - SCOPUS:77953725855

VL - 362

SP - 2260

EP - 2270

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 24

ER -